Debt-to-equity of Viracta Therapeutics, Inc. from 30 Jun 2019 to 30 Sep 2024

Taxonomy & unit: ratio: %
Description: Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary: Viracta Therapeutics, Inc. quarterly Debt-to-equity in % history and change rate from 30 Jun 2019 to 30 Sep 2024.
Viracta Therapeutics, Inc. Debt-to-equity for the quarter ending 30 Sep 2024 was 494%.

Debt-to-equity, Quarterly (%)

Debt-to-equity, YoY Quarterly Change (%)

Viracta Therapeutics, Inc. Quarterly Debt-to-equity (%)

Period	Value	YoY Chg	Change %	Date
Q3 2024	494%			30 Sep 2024
Q2 2024	215%			30 Jun 2024
Q1 2024	141%			31 Mar 2024
Q4 2020	-16%	-135%	-114%	31 Dec 2020
Q3 2020	-23%	-113%	-126%	30 Sep 2020
Q2 2020	-58%	-253%	-129%	30 Jun 2020
Q1 2020	-221%			31 Mar 2020
Q4 2019	119%			31 Dec 2019
Q3 2019	90%			30 Sep 2019
Q2 2019	196%			30 Jun 2019

* An asterisk sign (*) next to the value indicates that the value is likely invalid.